Dr Nicola Normanno was born in Ottaviano (Italy) in 1964 and graduated cum laude in Medicine and Surgery in 1988. He worked as postdoctoral fellow in the National Cancer Institute of Bethesda (USA), then he specialized in Medical Oncology and later in Hematology. In 2004 he won the “Annals of Oncology Prize for Translational Research” and in 2005 he became Adjunct Associate Professor at the Temple University of Philadelphia. From 2005 he has been appointed as Director of the Cell Biology and Biotherapy Unit of INT Fondazione “G. Pascale” and from 2006 he is the Chairman of the Research Department of the same institute.
Dr. Normanno leads a research group involved in both pre-clinical and clinical studies, with particular regard to the identification of biomarkers associated with sensitivity/resistance to target-based agents in clinical development. Dr. Normanno’s group has been one of the first to use next generation sequencing (NGS)-based techniques in clinical trials. His group has a relevant expertise in liquid biopsy. Dr. Normanno is also involved in clinical diagnostics and in the organization of national and international external quality assessment (EQA) schemes in molecular pathology.
Dr Normanno is a member of many national and international cancer research associations (AACR, GOIM, AIOT, ESMO, AIOM, SIC, FONICAP).He is President Elect of the Italian Society of Cancerology (SIC). Dr. Normanno is author of more than 200 publications in international journals and he is a reviewer for many peer reviewed journals.
Updated: November 2021